CTRS is a pharmaceutical company engaged since its creation to bring innovative, effective and safe treatments to patients suffering from rare or ultra-rare diseases where unmet need is high. We developed many public-private partnerships and believe that by working hand in hand with academic structures we will be able to find, develop and market the treatments of tomorrow.
Staff of 20+ employees
With strong experience in rare diseases
3 marketed and 3 in development
CTRS is present in over 20 countries directly or through partners
Multiple myeloma is a lymphoid malignant blood disease. It’s characterized by the multiplication of abnormal plasma cells in the bone marrow.
Primary bile acid synthesis disorders are very rare diseases of the liver. They are genetic autosomal recessive diseases resulting in cholestasis, then liver cirrhosis or progressive and irreversible liver failure in most cases in infants and children.
“Exploring (rare) cholestasis” is a free-access website reserved for healthcare professionals and dedicated to providing information about: